Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
MWN-AI** Summary
Genentech recently announced the results of its Phase III persevERA study, which evaluated the investigational drug giredestrant in combination with palbociclib for patients with estrogen receptor-positive (ER-positive), HER2-negative locally advanced or metastatic breast cancer. Although the study did not achieve its primary objective of demonstrating a statistically significant improvement in progression-free survival compared to letrozole plus palbociclib, a numerical improvement was noted. The safety profile of the giredestrant and palbociclib combination was found to be manageable, with adverse events aligning with expectations based on previously known safety profiles.
Genentech, a member of the Roche Group, remains committed to enhancing treatment for ER-positive breast cancer. The company has seen success with its other studies, including the evERA trial, which recently led to the FDA accepting a New Drug Application based on its findings. In the coming weeks, Genentech plans to submit additional data from the Phase III lidERA study to the FDA, further solidifying its commitment to ER-positive breast cancer care.
The persevERA study is one of two Phase III trials focusing on first-line treatment in this patient population, with the second study, pionERA, anticipated to yield results in 2027. Genentech’s robust clinical development program for giredestrant encompasses multiple studies aimed at optimizing treatment across different stages of breast cancer.
Despite the mixed results from the persevERA study, Genentech's Chief Medical Officer, Dr. Levi Garraway, expressed confidence in giredestrant's potential to establish itself as a new standard-of-care option in ER-positive breast cancer treatment, relying on validated efficacy from earlier trials to guide future studies.
MWN-AI** Analysis
Genentech's recent update on the Phase III persevERA study for giredestrant in ER-positive advanced breast cancer presents a nuanced outlook for investors considering positions in the biotechnology sector, particularly within oncology. Although the study did not achieve its primary endpoint of a statistically significant improvement in progression-free survival (PFS) compared to the control, the observed numerical improvement and favorable tolerability profile suggest potential therapeutic value moving forward.
Despite the miss on statistical significance, the robust pipeline of giredestrant—culminating in multiple trials, including the pivotal lidERA and upcoming pionERA studies—reinforces a broader strategic vision for Genentech. Investors should note that the FDA has recently accepted the New Drug Application for giredestrant based on promising results from the evERA trial, which offers a pathway for revenue generation upon potential approval.
The biotech company’s commitment to advancing ER-positive breast cancer treatment is anchored by historical success and ongoing trials aimed at broadening giredestrant's application across different settings. The confidence articulated by Genentech's leadership conveys an inherent belief in the drug's potential to establish a new standard of care, especially given its manageable safety profile.
While short-term stock volatility may be expected following mixed trial results, the long-term investment thesis remains intact. The continued focus on robust clinical development aimed at identifying specific oncology subtypes suggests that investors should maintain positions in Genentech, particularly as additional trial results unfold, potentially enhancing product positioning within the competitive oncology landscape.
In summary, Genentech's broadening pipeline, combined with its commitment to innovative cancer therapies and potential FDA approvals, provides a compelling case for maintaining a bullish outlook despite recent setbacks in the persevERA study.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- persevERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed
- Giredestrant plus palbociclib was well tolerated and adverse events were consistent with the known safety profiles of each individual treatment
- Genentech is committed to transforming ER-positive breast cancer care, anchored by the landmark success of lidERA in early-stage disease and evERA in the advanced setting
- The FDA recently accepted the New Drug Application based on evERA data; Phase III lidERA data will be submitted to the FDA in the coming weeks
- persevERA is the first of two distinct Phase III studies in the first-line setting; pionERA study of giredestrant in combination with physician’s choice of CDK4/6 inhibitor in endocrine-resistant ER-positive breast cancer is expected to readout in 2027
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from the Phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination with palbociclib for people with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer. The study did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed. The adverse events for the giredestrant combination were manageable and consistent with the known safety profiles of each individual treatment.
“While persevERA didn’t meet its primary objective, we are confident in the potential of giredestrant to become a new standard-of-care endocrine therapy in early and advanced ER-positive breast cancer," said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We believe there is a path forward for combining giredestrant with a CDK4/6 inhibitor in the adjuvant setting and we are conducting further studies. The efficacy demonstrated in evERA and lidERA provides clear validation of the clinical activity of giredestrant and reinforces the strength of our expanding clinical development program.”
The giredestrant clinical development program is made up of distinct studies designed to reflect the specific disease biology of each stage of breast cancer. Genentech will continue to advance the clinical development program to identify the people with ER-positive breast cancer who can derive the greatest benefit from giredestrant.
Giredestrant Phase III clinical development program
Trial | Indication | Regimen |
lidERA Breast Cancer | Adjuvant ER+/HER2- breast cancer | Giredestrant vs. standard-of-care endocrine therapy (SoC ET) |
persevERA Breast Cancer | 1L ER+/HER2- metastatic breast cancer (endocrine-sensitive) | Giredestrant + palbociclib vs. letrozole plus palbociclib |
pionERA Breast Cancer | 1L ER+/HER2- metastatic breast cancer (endocrine-resistant) | Giredestrant + physician’s choice of CDK4/6 inhibitor vs. fulvestrant + physician’s choice of CDK4/6 inhibitor |
evERA Breast Cancer | 2L+ ER+/HER2- metastatic breast cancer | Giredestrant + everolimus vs. SoC ET + everolimus |
heredERA Breast Cancer | 1L maintenance ER+/HER2+ metastatic breast cancer | Giredestrant + dual HER2 blockade vs. HER2 blockade |
evERA was the first positive Phase III readout for giredestrant, followed by lidERA in the early-stage setting. The scientific rationale for lidERA was supported by prior results in the neoadjuvant setting, including the Phase II coopERA trial showing that giredestrant was superior to an aromatase inhibitor in reducing malignant cell division (Ki67 levels). This growing body of evidence underscores the potential of giredestrant to become a new standard-of-care endocrine therapy across ER-positive early-stage and advanced breast cancer.
persevERA is the first of two distinct Phase III studies in the first-line setting; the pionERA study of giredestrant in combination with physician’s choice of cyclin-dependent kinase (CDK)4/6 inhibitor in endocrine-resistant ER-positive, HER2-negative breast cancer is expected to readout in 2027.
The United States Food and Drug Administration (FDA) recently accepted the New Drug Application based on the evERA data. In the coming weeks, Genentech will submit the giredestrant Phase III lidERA data in early-stage breast cancer to the FDA.
The full results from persevERA will be presented at an upcoming medical meeting.
About the persevERA Breast Cancer study
persevERA Breast Cancer [ NCT04546009 ] is a Phase III, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of giredestrant plus palbociclib versus letrozole plus palbociclib as first-line treatment for people with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer. The study enrolled 992 patients globally.
The primary endpoint is investigator-assessed progression-free survival. Key secondary endpoints include overall survival, objective response rate, duration of response and safety.
About giredestrant
Giredestrant is an investigational, oral, potent next-generation selective estrogen receptor degrader and full antagonist.
Giredestrant is designed to block estrogen from binding to the estrogen receptor (ER), triggering its breakdown (known as degradation) and stopping or slowing down the growth of cancer cells.
Giredestrant has an extensive clinical development program and is being investigated in five company-sponsored Phase III clinical trials that span multiple treatment settings and lines of therapy to benefit as many people as possible:
- Giredestrant versus standard-of-care endocrine therapy (SoC ET) as adjuvant treatment in ER-positive, human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer (lidERA Breast Cancer; NCT04961996 )
- Giredestrant plus everolimus versus SoC ET plus everolimus in ER-positive, HER2-negative, locally advanced or metastatic breast cancer (evERA Breast Cancer; NCT05306340 )
- Giredestrant plus palbociclib versus letrozole plus palbociclib in ER-positive, HER2-negative, endocrine-sensitive, recurrent locally advanced or metastatic breast cancer (persevERA Breast Cancer; NCT04546009 )
- Giredestrant plus investigator’s choice of a cyclin-dependent kinase (CDK)4/6 inhibitor versus fulvestrant plus a CDK4/6 inhibitor in ER-positive, HER2-negative advanced breast cancer resistant to adjuvant endocrine therapy (pionERA Breast Cancer; NCT06065748 )
- Giredestrant plus dual HER2 blockade versus dual HER2 blockade in ER-positive, HER2-positive locally advanced or metastatic breast cancer (heredERA Breast Cancer; NCT05296798 )
About estrogen receptor (ER)-positive breast cancer
Globally, the burden of breast cancer continues to grow, with 2.3 million women diagnosed and 670,000 dying from the disease every year. Breast cancer remains the number one cause of cancer-related deaths amongst women, and the second most common cancer type.
ER-positive breast cancer accounts for approximately 70% of breast cancer cases. In the U.S. and EU5, an estimated 273,000 people are diagnosed in the early-stage setting, 88,000 people are diagnosed in first-line and 106,000 in the second and third-line setting combined.
A defining feature of ER-positive breast cancer is that its tumor cells have receptors that attach to estrogen, which can contribute to tumor growth.
Despite treatment advances, ER-positive breast cancer remains particularly challenging to treat due to its biological complexity. In the early-stage setting, up to a third of people eventually experience disease recurrence on or after adjuvant endocrine therapy treatment. Additionally, many have to interrupt or stop treatment early due to safety or tolerability issues, thereby increasing the risk of death. In advanced settings, resistance to endocrine therapy – particularly following treatment with cyclin-dependent kinase inhibitors – increases the risk of disease progression and is associated with poor outcomes.
There is an urgent need for more effective treatments that can delay clinical progression and reduce the burden of treatment on people’s lives.
About Genentech in Breast Cancer
Genentech has been advancing breast cancer research for more than 30 years with the goal of helping as many people with the disease as possible. Our medicines, along with companion diagnostic tests, have contributed to bringing breakthrough outcomes in multiple types of breast cancers. As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for other subtypes of the disease, including estrogen receptor-positive breast cancer, which is a form of hormone receptor-positive breast cancer, the most prevalent type of all breast cancers.
About Genentech
Founded 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260308597396/en/
Media Contact: Jared Preston (650) 467-6800
Advocacy Contact: Julie Burns (860) 881-6594
Investor Contacts: Loren Kalm (650) 225-3217
Bruno Eschli +41 61 68-75284
FAQ**
What implications does the numerical improvement observed in the persevERA study, despite not meeting the primary objective, have for the future development and market positioning of giredestrant in the competitive landscape, particularly for Roche Holding Ltd ADR RHHBY?
Given the manageable adverse events noted in the persevERA study for giredestrant, how might this influence prescribing trends among oncologists and the market perception of Roche Holding Ltd ADR RHHBY's commitment to safer treatment options?
How does the FDA's acceptance of the New Drug Application based on evERA data affect investor confidence in Roche Holding Ltd ADR RHHBY, and what potential market opportunities could arise from this development?
With the ongoing giredestrant clinical development program and the expected readout of pionERA in 2027, what strategies should Roche Holding Ltd ADR RHHBY adopt to communicate these advancements to investors and stakeholders effectively?
**MWN-AI FAQ is based on asking OpenAI questions about Roche Holding Ltd ADR (OTC: RHHBY).
NASDAQ: RHHBY
RHHBY Trading
-3.67% G/L:
$52.925 Last:
482,453 Volume:
$52.32 Open:
